The 2018 Farm Bill legalized the sale of hemp-derived products and directed USDA to develop federal hemp regulations. However, the legislation did not change FDA’s authority to regulate products derived from cannabis or hemp under the Federal Food, Drug, and Cosmetic Act. FDA has not yet lifted restrictions on the inclusion of CBD in products, but has made such determinations with regard to hemp seed, hemp oil, and hemp protein. Illustratively, the lack of current guidance or rules from USDA and FDA on the implementation of the 2018 Farm Bill, in conjunction with the patchwork of state laws and regulations, has made the path forward for the cannabis and hemp industries more murky than ever. During this session, panelists will discuss the current regulatory landscape, both federally and at a state level, and will provide insight on how to find regulatory Zen for this blossoming industry.  Speakers will include lawyers who specialize in the regulation of cannabis and hemp products, as well as representatives from industry. They will explore examples, including:

  • Cannabis in food, supplements, and cosmetics;
  • Labeling of cannabis-derived products;
  • Marketing of cannabis-derived products;
  • Sale of cannabis-derived products over the internet; and
  • Transportation of cannabis-derived products within and between states.


Seth A. Goldberg, Partner, Duane Morris LLP
Douglas (Duffy) MacKay, Senior Vice President, Scientific and Regulatory Affairs, CV Sciences
Ted Rebholz, CEO, Integrative Health Products
Moderated by Carolyn A. Alenci, Associate, Duane Morris LLP






Event Schedule

subject to change 

Tuesday, July 23

5:00 PM
Reception: Mix and Mingle with Peers

5:45 – 7:00 PM
Panel Discussion


Event Location

Duane Morris LLP
100 High Street, Suite 2400
Boston, MA 02110